In short
This article summarizes clinical trials investigating the use of a pneumococcal vaccine containing pneumococcal polysaccharide serotype 19A conjugated to CRM197 and adsorbed on aluminium phosphate. The vaccine is being studied in various populations including healthy adults, infants, and those at increased risk of pneumococcal disease. The trials aim to evaluate the safety, immunogenicity, and effectiveness of this vaccine formulation against pneumococcal infections.
At a glance
- Populations studied
- Healthy adults, infants, adults aged 18-64 with increased risk, adults aged 65+
- Vaccine formulations
- 20-valent pneumococcal conjugate vaccine (PCV20), 13-valent pneumococcal conjugate vaccine (PCV13)
- Key outcomes measured
- Immune responses, safety/tolerability, effectiveness against pneumococcal diseases
- Study designs
- Randomized controlled trials, open-label studies, test-negative design
- Duration of follow-up
- Ranging from several months to 2 years
- Comparator vaccines
- PCV13, 23-valent pneumococcal polysaccharide vaccine (PPSV23)
- Special populations
- Individuals with increased risk of pneumococcal disease, older adults
What is the pneumococcal polysaccharide serotype 19A conjugate vaccine?
The pneumococcal polysaccharide serotype 19A conjugate vaccine is a component of broader pneumococcal conjugate vaccines like Prevnar 13 and Apexxnar. It specifically targets the 19A serotype of Streptococcus pneumoniae, a bacterium that can cause serious infections.
This vaccine contains purified capsular polysaccharide from the 19A serotype that is chemically linked (conjugated) to a non-toxic variant of diphtheria toxin called CRM197. The conjugate is then adsorbed onto an aluminum phosphate adjuvant to enhance the immune response.
How does it work?
The vaccine works by stimulating the immune system to produce antibodies against the capsular polysaccharide of the 19A serotype of S. pneumoniae. The conjugation to CRM197 helps to induce a stronger, longer-lasting immune response, especially in young children.
When vaccinated individuals are later exposed to the 19A serotype, their immune system can quickly recognize and neutralize the bacteria, preventing infection or reducing its severity.
What is it used for?
This vaccine component helps protect against invasive pneumococcal disease (IPD) caused by the 19A serotype, including:
- Pneumonia (lung infection)
- Bacteremia (blood infection)
- Meningitis (infection of the membranes covering the brain and spinal cord)
It is particularly important because the 19A serotype has become more prevalent and is often associated with antibiotic resistance.
How is it administered?
The vaccine is typically given as an intramuscular injection, usually in the thigh for infants or the upper arm for older children and adults. It is administered as part of broader pneumococcal conjugate vaccines that protect against multiple serotypes.
The dosing schedule varies depending on the age at which vaccination begins:
- Infants usually receive a series of doses at 2, 4, 6, and 12-15 months of age
- Older children and adults may receive fewer doses, depending on their age and health status
How effective is it?
Clinical trials have shown that pneumococcal conjugate vaccines containing the 19A serotype are highly effective at preventing invasive pneumococcal disease caused by this strain. For example, studies have demonstrated:
- A significant reduction in IPD cases caused by serotype 19A after the introduction of vaccines containing this component
- Strong immune responses in both children and adults, with high levels of protective antibodies produced
What are the potential side effects?
Most side effects of pneumococcal conjugate vaccines are mild and short-lived. Common side effects may include:
- Pain, redness, or swelling at the injection site
- Fever
- Irritability in infants
- Fatigue
- Headache (in older children and adults)
Serious side effects are rare but can include severe allergic reactions. Patients should seek medical attention if they experience signs of a severe allergic reaction after vaccination.
Who should get this vaccine?
Pneumococcal conjugate vaccines containing the 19A serotype are recommended for:
- All infants and young children as part of their routine vaccination schedule
- Adults 65 years and older
- Individuals with certain medical conditions that increase their risk of pneumococcal disease, such as:
- Chronic heart, lung, or liver disease
- Diabetes
- Weakened immune systems
Your healthcare provider can advise if this vaccine is appropriate for you based on your age, health status, and vaccination history.
Ongoing research
Researchers continue to study pneumococcal conjugate vaccines to improve their effectiveness and broaden protection. Some areas of ongoing research include:
- Developing vaccines that cover even more serotypes
- Studying the long-term effectiveness and impact on pneumococcal disease patterns
- Investigating the potential for co-administration with other vaccines
These studies aim to further enhance protection against pneumococcal infections and optimize vaccination strategies for different populations.